Literature DB >> 25686758

Multiple sclerosis-a quiet revolution.

Richard M Ransohoff1, David A Hafler2, Claudia F Lucchinetti3.   

Abstract

Multiple sclerosis (MS) has been thought to be a complex and indecipherable disease, and poorly understood with regards to aetiology. Here, we suggest an emphatically positive view of progress over several decades in the understanding and treatment of MS, particularly focusing on advances made within the past 20 years. As with virtually all complex disorders, MS is caused by the interaction of genetic and environmental factors. In recent years, formidable biochemical, bioinformatic, epidemiological and neuroimaging tools have been brought to bear on research into the causes of MS. While susceptibility to the disease is now relatively well accounted for, disease course is not and remains a salient challenge. In the therapeutic realm, numerous agents have become available, reflecting the fact that the disease can be attacked successfully at many levels and using varied strategies. Tailoring therapies to individuals, risk mitigation and selection of first-line as compared with second-line medications remain to be completed. In our view, the MS landscape has been comprehensively and irreversibly transformed by this progress. Here we focus on MS therapeutics-the most meaningful outcome of research efforts.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25686758      PMCID: PMC4556342          DOI: 10.1038/nrneurol.2015.14

Source DB:  PubMed          Journal:  Nat Rev Neurol        ISSN: 1759-4758            Impact factor:   42.937


  89 in total

Review 1.  Epidemiology and genetics of multiple sclerosis.

Authors:  A Compston; A D Sadovnick
Journal:  Curr Opin Neurol Neurosurg       Date:  1992-04

Review 2.  Inflammatory neurological disease in patients treated with tumor necrosis factor alpha inhibitors.

Authors:  Andrew J Solomon; Rebecca I Spain; Michael C Kruer; Dennis Bourdette
Journal:  Mult Scler       Date:  2011-08-03       Impact factor: 6.312

Review 3.  Humoral-targeted immunotherapies in multiple sclerosis.

Authors:  Sabeen Lulu; Emmanuelle Waubant
Journal:  Neurotherapeutics       Date:  2013-01       Impact factor: 7.620

Review 4.  Immune-mediated disease genetics: the shared basis of pathogenesis.

Authors:  Chris Cotsapas; David A Hafler
Journal:  Trends Immunol       Date:  2012-09-29       Impact factor: 16.687

5.  Predictors of long-term outcome in multiple sclerosis patients treated with interferon β.

Authors:  Robert A Bermel; Xiaojun You; Pamela Foulds; Robert Hyde; Jack H Simon; Elizabeth Fisher; Richard A Rudick
Journal:  Ann Neurol       Date:  2013-01       Impact factor: 10.422

6.  Real-life impact of early interferon beta therapy in relapsing multiple sclerosis.

Authors:  M Trojano; F Pellegrini; D Paolicelli; A Fuiani; G B Zimatore; C Tortorella; I L Simone; F Patti; A Ghezzi; V Zipoli; P Rossi; C Pozzilli; G Salemi; A Lugaresi; R Bergamaschi; E Millefiorini; M Clerico; G Lus; M Vianello; C Avolio; P Cavalla; V Lepore; P Livrea; G Comi; M P Amato
Journal:  Ann Neurol       Date:  2009-10       Impact factor: 10.422

7.  B cells populating the multiple sclerosis brain mature in the draining cervical lymph nodes.

Authors:  Joel N H Stern; Gur Yaari; Jason A Vander Heiden; George Church; William F Donahue; Rogier Q Hintzen; Anita J Huttner; Jon D Laman; Rashed M Nagra; Alyssa Nylander; David Pitt; Sriram Ramanan; Bilal A Siddiqui; Francois Vigneault; Steven H Kleinstein; David A Hafler; Kevin C O'Connor
Journal:  Sci Transl Med       Date:  2014-08-06       Impact factor: 17.956

8.  Natalizumab in the treatment of multiple sclerosis.

Authors:  Brandon A Brown
Journal:  Ther Clin Risk Manag       Date:  2009-08-03       Impact factor: 2.423

9.  Alemtuzumab vs. interferon beta-1a in early multiple sclerosis.

Authors:  Alasdair J Coles; D Alastair S Compston; Krzysztof W Selmaj; Stephen L Lake; Susan Moran; David H Margolin; Kim Norris; P K Tandon
Journal:  N Engl J Med       Date:  2008-10-23       Impact factor: 91.245

10.  The relation between inflammation and neurodegeneration in multiple sclerosis brains.

Authors:  Josa M Frischer; Stephan Bramow; Assunta Dal-Bianco; Claudia F Lucchinetti; Helmut Rauschka; Manfred Schmidbauer; Henning Laursen; Per Soelberg Sorensen; Hans Lassmann
Journal:  Brain       Date:  2009-03-31       Impact factor: 13.501

View more
  115 in total

Review 1.  Neuroimmunotherapies Targeting T Cells: From Pathophysiology to Therapeutic Applications.

Authors:  Stefan Bittner; Heinz Wiendl
Journal:  Neurotherapeutics       Date:  2016-01       Impact factor: 7.620

2.  IL-17A Promotes Granulocyte Infiltration, Myelin Loss, Microglia Activation, and Behavioral Deficits During Cuprizone-Induced Demyelination.

Authors:  Julian Zimmermann; Michael Emrich; Marius Krauthausen; Simon Saxe; Louisa Nitsch; Michael T Heneka; Iain L Campbell; Marcus Müller
Journal:  Mol Neurobiol       Date:  2017-01-13       Impact factor: 5.590

3.  Prolonged stimulation of a brainstem raphe region attenuates experimental autoimmune encephalomyelitis.

Authors:  Pernille M Madsen; Stephanie S Sloley; Alberto A Vitores; Melissa M Carballosa-Gautam; Roberta Brambilla; Ian D Hentall
Journal:  Neuroscience       Date:  2017-01-29       Impact factor: 3.590

Review 4.  Epigenetics in NG2 glia cells.

Authors:  Sarah Moyon; Jialiang Liang; Patrizia Casaccia
Journal:  Brain Res       Date:  2015-06-17       Impact factor: 3.252

5.  Corrigendum: multiple sclerosis-a quiet revolution.

Authors:  Richard M Ransohoff; David A Hafler; Claudia F Lucchinetti
Journal:  Nat Rev Neurol       Date:  2015-03-24       Impact factor: 42.937

6.  Platelets Play Differential Role During the Initiation and Progression of Autoimmune Neuroinflammation.

Authors:  Sarah C Starossom; Tatyana Veremeyko; Amanda W Y Yung; Marina Dukhinova; Cheryl Au; Alexander Y Lau; Howard L Weiner; Eugene D Ponomarev
Journal:  Circ Res       Date:  2015-08-20       Impact factor: 17.367

7.  Stem Cell-Derived Exosomes as Nanotherapeutics for Autoimmune and Neurodegenerative Disorders.

Authors:  Milad Riazifar; M Rezaa Mohammadi; Egest J Pone; Ashish Yeri; Cecilia Lässer; Aude I Segaliny; Laura L McIntyre; Ganesh Vilas Shelke; Elizabeth Hutchins; Ashley Hamamoto; Erika N Calle; Rossella Crescitelli; Wenbin Liao; Victor Pham; Yanan Yin; Jayapriya Jayaraman; Jonathan R T Lakey; Craig M Walsh; Kendall Van Keuren-Jensen; Jan Lotvall; Weian Zhao
Journal:  ACS Nano       Date:  2019-05-29       Impact factor: 15.881

8.  Adenosine Promotes the Recovery of Mice from the Cuprizone-Induced Behavioral and Morphological Changes while Effecting on Microglia and Inflammatory Cytokines in the Brain.

Authors:  Jinling Zhang; Liu Yang; Zeman Fang; Jiming Kong; Qingjun Huang; Haiyun Xu
Journal:  J Neuroimmune Pharmacol       Date:  2018-08-01       Impact factor: 4.147

Review 9.  Melatonin and Multiple Sclerosis: From Plausible Neuropharmacological Mechanisms of Action to Experimental and Clinical Evidence.

Authors:  Mahshid Yeganeh Salehpour; Adriano Mollica; Saeideh Momtaz; Nima Sanadgol; Mohammad Hosein Farzaei
Journal:  Clin Drug Investig       Date:  2019-07       Impact factor: 2.859

10.  PET Imaging Study of S1PR1 Expression in a Rat Model of Multiple Sclerosis.

Authors:  Hui Liu; Hongjun Jin; Xuyi Yue; Zonghua Luo; Chunling Liu; Adam J Rosenberg; Zhude Tu
Journal:  Mol Imaging Biol       Date:  2016-10       Impact factor: 3.488

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.